Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis

Hepatology

Volumn 47, Issue 1, 2008, Pages 71-81

  Kulik, Laura M ^a   Carr, Brian I ^b   Mulcahy, Mary F ^c   Lewandowski, Robert J ^c   Atassi, Bassel ^c   Ryu, Robert K ^c   Sato, Kent T ^c   Benson III, Al ^c   Nemcek Jr , Albert A ^c   Gates, Vanessa L ^c   Abecassis, Michael ^c   Omary, Reed A ^c   Salem, Riad ^c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^d Department of Radiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; YTTRIUM 90; MICROSPHERE; YTTRIUM;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; ARTIFICIAL EMBOLISM; BRACHYTHERAPY; CLINICAL TRIAL; FEMALE; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PORTAL VEIN; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PORTAL VEIN; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS; YTTRIUM RADIOISOTOPES;

EID: 38649127852     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21980     Document Type: Article

References (30)

1. Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, et al. Incidence of portal vein thrombosis in liver cirrhosis: an angiographic study in 708 patients. Gastroenterology 1985;89:279-286.
2. Davidson BR, Gibson M, Dick R, Burroughs A, Rolles K. Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation 1994;57:1174-1177.
3. Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma ZC, et al. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 2001;7:28-32.
4. Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-665.
5. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
6. Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 1993; 4:347-351.
7. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S211-S221.
8. Llovet J, Ricci S, Mazzafero V, Hilgard P, Raoul J, Zeuzem S, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP). American Society of Clinical Oncology (ASCO) Annual Meeting 2007, Chicago, IL.
9. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10(Suppl 1):S107-S110.
10. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(Suppl 1):S194-S205.
11. Goin JE, Dancey JE, Roberts CA, Sickles CJ, Leung DA, Soulen MC. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemoembolization versus yttrium-90 glass microspheres. World J Nucl Med 2004;3:49-56.
12. Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;29:522-529.
13. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-345.
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
15. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10: 239-253.
16. TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada, 2004.
17. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13(Suppl):S223-S229.
18. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251-1278.
19. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33:919-924.
20. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-1261.
21. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular Carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 5:588-595.
22. Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999;19:399-414.
23. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. HEPATOLOGY 2002;35:1164-1171.
24. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997;79:2087-2094.
25. Carr BI. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 2002;49:79-86.
26. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10(Suppl 1):S115-S120.
27. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-928.
28. Llovet JM, Bruix J. Systematic teview of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. HEPATOLOGY 2003;37:429-442.
29. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. HEPATOLOGY 1999;29:62-67.
30. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42:1208-1236.